[Editor's Note: At its 14 February meeting, FDA's circulatory system devices panel voted nearly unanimously in favor of Abbott's TriClip G4, including a 13-1 vote in favor of concluding that the benefits of the technology outweigh its risks. Medtech Insight will have more on TriClip G4 later this week.]
Analysts expect the US Food and Drug Administration to approve Abbott ’s TriClip G4 transcatheter tricuspid valve repair (TTVR) system,
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?